The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat
Abstract
The incretin hormone glucagon-like peptide-1 (GLP-1) is released from the gut in response to fat or carbohydrate and contributes to negative feedback control of blood glucose by stimulating insulin secretion, inhibiting glucagon, and slowing gastric emptying. GLP-1 receptors (GLP-1R) are also expressed in the proximal tubule, and possibly elsewhere in the kidney. Presently, we examined the effect of a GLP-1R agonist on single-nephron glomerular filtration rate (GFR; SNGFR), proximal reabsorption ( Jprox), tubuloglomerular feedback (TGF) responses, and urine flow rate in hydropenic male Wistar and Wistar-Froemter rats. Micropuncture and whole-kidney data were obtained before and during infusion of the GLP-1 agonist exenatide (1 nmol/h iv). SNGFR and Jprox were measured by late proximal collection at both extremes of TGF activation, which was achieved by perfusing Henle's loop at 0 or 50 nl/min. Primary changes in Jprox were revealed by analysis of covariance for Jprox with SNGFR as a covariate. Effects on TGF activation were determined in a separate set of experiments by comparing early distal and late proximal collections. Exenatide increased SNGFR by 33–50%, suppressed proximal tubular reabsorption by 20–40%, doubled early distal flow rate, and increased urine flow rate sixfold without altering the efficiency of glomerulotubular balance, TGF responsiveness, or the tonic influence of TGF. This implies that exenatide is both a proximal diuretic and a renal vasodilator. Since the natural agonist for the GLP-1R is regulated by intake of fat and carbohydrate, but not by salt or fluid, the control of salt excretion by the GLP-1R system departs from the usual negative-feedback paradigm for regulating salt balance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 receptor agonists exert direct effects to increase glomerular filtration rate and inhibit proximal renal tubular sodium reabsorption, thus influencing tubuloglomerular feedback in states of glomerular hyperfiltration.30-32”
From Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 1×
“GLP-1R is expressed in human renal arteries (17).”
BackgroundGlucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442
Thomson, S. C., Rieg, T., Miracle, C., Mansoury, H., Whaley, J., Vallon, V., & Singh, P. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00357.2011 · Cited by 315
Self-citationCrajoinas, R. O., Oricchio, F. T., Pessoa, T. D., Pacheco, B. P. M., Lessa, L. M. A., Malnic, G., & Girardi, A. C. C. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00729.2010 · Cited by 278 · cited 2×
“GLP-1R mRNA is found in rat glomeruli and proximal tubules (5), and recombinant GLP-1 infusion vasodilates the rat kidney (5), more so with intact renal nerves (21).”
BackgroundAntihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
Yu, M., Moreno, C., Hoagland, K. M., Dahly, A., Ditter, K., Mistry, M., & Roman, R. J. (2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00012 · Cited by 273
Micropuncture study of net transtubular movement of water and urea in nondiuretic mammalian kidney
Lassiter, W. E., Gottschalk, C. W., & Mylle, M. (1961) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1961.200.6.1139 · Cited by 269
What do we know about the secretion and degradation of incretin hormones?
Deacon, C. F. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.007 · Cited by 241
Thomson, S. C., Deng, A., Bao, D., Satriano, J., Blantz, R. C., & Vallon, V. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10963 · Cited by 236
Self-citationGlucagon-Like Peptide 1 Secretion by the L-Cell
Lim, G. E., & Brubaker, P. L. (2006) · Diabetes · doi:10.2337/db06-s020 · Cited by 223
Nutritional regulation of glucagon‐like peptide‐1 secretion
Tolhurst, G., Reimann, F., & Gribble, F. M. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2008.164012 · Cited by 214
Dumoulin, V. (1998) · Endocrinology · doi:10.1210/en.139.9.3780 · Cited by 167
The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent
Furman, B. L. (2012) · Toxicon · doi:10.1016/j.toxicon.2010.12.016 · Cited by 166 · cited 2×
“Those metabolic effects of exenatide extended over 3 log orders, with EC50 and EC90 for lowering HbA1C being 20 pM and 1 nM, respectively (11).”
BackgroundExendin-4 has an anti-hypertensive effect in salt-sensitive mice model
Hirata, K., Kume, S., Araki, S.-I., Sakaguchi, M., Chin-Kanasaki, M., Isshiki, K., Sugimoto, T., Nishiyama, A., Koya, D., Haneda, M., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.003 · Cited by 163
Pharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1
Parkes, D., Jodka, C., Smith, P., Nayak, S., Rinehart, L., Gingerich, R., Chen, K., & Young, A. (2001) · Drug Development Research · doi:10.1002/ddr.1195 · Cited by 158
Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells
Schlatter, P., Beglinger, C., Drewe, J., & Gutmann, H. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2006.12.016 · Cited by 149
Girardi, A. C. C., DeGray, B., Nagy, T., Biemesderfer, D., & Aronson, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106897200 · Cited by 129
Minireview: Update on Incretin Biology: Focus on Glucagon-Like Peptide-1
Brubaker, P. L. (2010) · Endocrinology · doi:10.1210/en.2010-0115 · Cited by 122
Renal effects of glucagon-like peptide in rats
Moreno, C., Mistry, M., & Roman, R. J. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01542-4 · Cited by 121
Glomerulotubular Balance, Tubuloglomerular Feedback, and Salt Homeostasis
Thomson, S. C., & Blantz, R. C. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007121326 · Cited by 116
Self-citationD’Alessio, D. A., Lu, W. J., Sun, W. Y., Zheng, S., Yang, Q., Seeley, R. J., Woods, S. C., & Tso, P. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00911.2006 · Cited by 112
Homeostasis: a plea for a unified approach
Carpenter, R. H. S. (2004) · AJP Advances in Physiology Education · doi:10.1152/advan.00012.2004 · Cited by 109
Westle, B. (1998) · Oxford University Press eBooks · doi:10.1093/019829476x.003.0013 · Cited by 98
Klein, J. D., Blount, M. A., & Sands, J. M. (2011) · Comprehensive physiology · doi:10.1002/cphy.c100030 · Cited by 94
Yang, J., Campitelli, J., Hu, G., Lin, Y., Luo, J. J., & Xue, C. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.04.040 · Cited by 94
Fehmann, H. C., Jiang, J., Schweinfurth, J., Wheeler, M. B., BOYD, A. E., & Göke, B. (1994) · Peptides · doi:10.1016/0196-9781(94)90204-6 · Cited by 93
Gedulin, B. R., Smith, P., Prickett, K. S., Tryon, M. S., Barnhill, S. D., Reynolds, J., Nielsen, L. L., Parkes, D. G., & Young, A. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1795-2 · Cited by 82
The incretins: a link between nutrients and well-being
Burcelin, R. (2005) · British Journal Of Nutrition · doi:10.1079/bjn20041340 · Cited by 78
Thomson, S. C., & Blantz, R. C. (1993) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1993.264.6.f930 · Cited by 68
Self-citationIncreased tubular flow induces resetting of tubuloglomerular feedback in euvolemic rats
Thomson, S. C., Blantz, R. C., & Vallon, V. (1996) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1996.270.3.f461 · Cited by 62
Self-citationYoder, S. M., Yang, Q., Kindel, T. L., & Tso, P. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00432.2009 · Cited by 46
Exenatide Improves Hypertension in a Rat Model of the Metabolic Syndrome
Laugero, K. D., Stonehouse, A. H., Guss, S., Landry, J., Vu, C., & Parkes, D. G. (2009) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2008.0095 · Cited by 44
Reduced proximal reabsorption resets tubuloglomerular feedback in euvolemic rats
Thomson, S. C., Vallon, V., & Blantz, R. C. (1997) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1997.273.4.r1414 · Cited by 36
Self-citationSingh, P., Deng, A., Blantz, R. C., & Thomson, S. C. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90722.2008 · Cited by 24
Self-citationViereck, C., & Boudes, P. F. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.01.009 · Cited by 18
Nowicki, S., Opezzo, J. A. W., Levin, G. M., Gonzalez, D. C., & Elı́as, M. M. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10660-5 · Cited by 2
Research works printed but not linked: 2
- 10.1210/endo.139.9.6202 · doi:10.1210/endo.139.9.6202 · Paper page
- Thomson SC, 1997, Am J Physiol Renal Physiol, 273, F1414
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Consistent with this, GLP-1, exendin-4, and the DPP-4 inhibitor sitagliptin reduced proximal tubular sodium reabsorption in rats [660,761,769,770] and humans [663].”
BackgroundPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040947 · Cited by 144
Metadata
- Authors
- Thomson, S. C., Kashkouli, A., & Singh, P.
- Affiliations
- Department of Medicine, University of California and Veterans Affairs San Diego Healthcare System, San Diego, California
- Venue
- American Journal of Physiology-Renal Physiology
- Publisher
- American Physiological Society
- Published
- 2013-01-15
- Volume
- 304
- Issue
- 2
- Pages
- F137-F144
- ISSN
- 1931-857X
- 1522-1466
- Cited by
- 71
- References
- 37
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.